Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
- 28 February 2007
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (2) , 196-202
- https://doi.org/10.4065/82.2.196
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trialsAmerican Heart Journal, 2004
- Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30‐day follow‐up studyCatheterization and Cardiovascular Interventions, 2002
- Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial InfarctionNew England Journal of Medicine, 2002
- Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial InfarctionNew England Journal of Medicine, 2001
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable AnginaCirculation, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994